Dow Q3 2025: Struggling at the Bottom of the Cycle Amid a Slow Structural Recovery
Dow Inc. released its third-quarter 2025 results on October 23, showing continued weakness across all business segments. Although sequential performance improved slightly, the year-on-year declines remain significant, underscoring persistent demand weakness, pricing pressure, and high input costs.
| Metric |
3Q25 |
3Q24 |
YoY Δ |
2Q25 |
QoQ Δ |
|---|---|---|---|---|---|
| Net Sales |
$9,973M |
$10,879M |
-8% (-$906M) |
$10,104M |
-1% |
| GAAP Net Income |
$124M |
$240M |
-48% (-$116M) |
-$801M |
+$925M |
| Operating EBIT |
$180M |
$641M |
-72% (-$461M) |
-$21M |
+$201M |
| Operating EBITDA |
$868M |
$1,382M |
-37% (-$514M) |
$703M |
+$165M |
| GAAP EPS |
$0.08 |
$0.30 |
-$0.22 |
-$1.18 |
+$1.26 |
| Operating Cash Flow (Cont. Ops) |
$1,130M |
$800M |
+41% (+$330M) |
-$470M |
+$1,600M |
Key takeaway: Dow remains under broad cyclical pressure, yet stronger cash flow and lower costs signal early signs of operational stabilization.
Packaging & Specialty Plastics: Profits Halved but Margins Recover Sequentially
| Metric |
3Q25 |
3Q24 |
YoY Δ |
2Q25 |
QoQ Δ |
|---|---|---|---|---|---|
| Net Sales |
$4,891M |
$5,516M |
-11% (-$625M) |
$5,025M |
-3% |
| Operating EBIT |
$199M |
$618M |
-68% (-$419M) |
$71M |
+179% (+$128M) |
| Equity Earnings |
-$6M |
$16M |
-$22M |
$7M |
-$13M |
This segment, Dow’s largest revenue contributor, faced a sharp profitability squeeze as polyethylene and polymer prices fell 10% year over year, alongside lower licensing revenue.
Sequentially, however, Operating EBIT rose sharply, driven by the new polyethylene unit in Freeport, Texas, higher utilization, and improved cost efficiency. Flexible packaging demand showed resilience, cushioning part of the decline, while supply disruptions at the Sadara JV have now normalized.
Industrial Intermediates & Infrastructure: Resilient Through Efficiency Gains
| Metric |
3Q25 |
3Q24 |
YoY Δ |
2Q25 |
QoQ Δ |
|---|---|---|---|---|---|
| Net Sales |
$2,834M |
$2,962M |
-$128M |
$2,786M |
+$48M |
| Operating EBIT |
-$47M |
-$53M |
+$6M |
-$185M |
+138M |
| Equity Earnings |
-$68M |
-$17M |
-$51M |
-$39M |
-$29M |
The Industrial Intermediates & Infrastructure (II&I) segment performed more steadily, supported by North American demand recovery and the new alkylation unit in Seadrift, Texas. While still loss-making, EBIT improved significantly quarter-over-quarter, reflecting lower maintenance downtime and improved plant efficiency.
Nevertheless, JV losses in Kuwait and Sadara widened, underscoring structural margin pressure in high-cost regions.
Performance Materials & Coatings: Margin Compression Persists
| Metric |
3Q25 |
3Q24 |
YoY Δ |
2Q25 |
QoQ Δ |
|---|---|---|---|---|---|
| Net Sales |
$2,082M |
$2,214M |
-$132M |
$2,129M |
-$47M |
| Operating EBIT |
$80M |
$140M |
-$60M |
$152M |
-$72M |
| Equity Earnings |
$1M |
$1M |
0 |
$1M |
0 |
Weakness in siloxanes and seasonal declines in coating applications weighed on profitability. Although fixed costs were reduced, EBIT margin erosion continued, reflecting softer consumer solutions demand and margin compression in upstream silicones. Dow plans further optimization of its high-value coatings and silicone product mix through 2026 to restore profitability.
Financial & Strategic Highlights
Dow’s revenue decline remains primarily price-driven: local prices dropped 8% year-on-year, while volumes declined 1%. EMEAI weakness was partially offset by gains in North America and Asia-Pacific. Sequentially, volumes rose 1%, signaling inventory normalization across the chain.
Operating EBIT fell $461M YoY, while EBITDA decreased $514M, but both metrics improved sequentially, supported by cost reduction initiatives.
GAAP EPS came in at $0.08 (vs. $0.30 YoY), and operating EPS at -$0.19, compared to $0.47 last year.
Notably, Dow recorded a one-time gain from divesting its 50% stake in the DowAksa JV and a favorable tax adjustment, mitigating part of the earnings decline.
Cash flow from operations rose 41% YoY to $1.13B, reflecting improved working capital efficiency and disciplined capital spending — a crucial signal of liquidity strength amid a weak profit cycle.
Outlook: Building a Floor, Not Yet a Turning Point
Dow’s Q3 results reflect a classic “bottoming” phase — sequential progress, but far from recovery. The global chemical industry remains in a late-stage destocking cycle, with subdued downstream demand and weak pricing power.
Operationally, Dow’s Gulf Coast investments are beginning to pay off, supporting volume recovery and lowering unit costs. If polyethylene and alkoxylation assets sustain utilization gains through 1H26, the company could emerge from the downturn earlier than peers.
However, Europe’s high-cost footprint and JV profitability erosion remain structural drags. In essence, Dow is in a cash restoration phase, not yet a profit inflection phase. True recovery will depend on global demand revival and further portfolio optimization.
Bottom line: Dow is stabilizing operationally but not yet growing financially. The company is managing through the trough — relying on cost discipline and capital efficiency — while waiting for the next upcycle to reignite margin expansion.
2026-10-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
BASF Battles Market Turmoil as Profits Slide
-
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
From Desert Sands to Dining Tables: Arab Food & Beverage Sector Emerges as Investment Powerhouse
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Exit! Why Did Clariant Divest Its Venezuelan Business at a “Low Price”?
Recommend Reading
-
Covestro Minority Shareholder Squeeze-Out Price Set at €59.46 per Share
-
BASF Raises European Amines by Up to 30% and LANXESS Raises Inorganic Pigments by Up to 20%
-
BASF Technology with CFRP Lands in Nanjing: High-Performance Dispersant Production Line Officially Commissioned
-
BASF’s €8.7 Billion Zhanjiang Verbund Site Fully Operational
-
Syensqo Launches AI-Developed Coffee Peptide for Scalp Care
-
Business Society’s Market Outlook for Styrene Butadiene Rubber on August 14, 2026: Short-Term Bullish Factors Support the Market
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
Business Society’s Methanol Market Outlook on August 18, 2026: Clearly Upward Trend
-
High-level Fluctuations, Weakening Momentum for Increase: May 2026 Natural Rubber Market Analysis in China
-
Business Society’s Market Outlook for Butadiene Rubber on August 14, 2026: Price Increase Driven by Positive Factors
- Hot Searches
- retatrutide peptide buy usa price near me
- bachem reta
- tirzepatide research peptide for sale
- gymtessa
- sodium potassium magnesium oral sol
- surfactant manufacturers
- tci 4-chlorobenzaldehyde 25 g price
- sodium.chloride
- caustic solutions
- white petroleum mineral oil
- ag chemi
- trifluoroacetic acid